Neumora Stock Hits Record Low on Depression Drug Study Failure
Portfolio Pulse from
Neumora's stock (NMRA) hit a record low after its experimental depression drug failed to meet key endpoints in a late-stage study.
January 03, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neumora's stock has reached a record low due to the failure of its experimental depression drug in a late-stage study, which did not meet primary and secondary endpoints.
The failure of the drug to meet primary and secondary endpoints in a late-stage study is a significant setback for Neumora, likely leading to a decrease in investor confidence and a drop in stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100